Comparative study of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: an interventional randomised clinical study in a tertiary care hospital


  • Robina Mirza Department of Obstetrics and Gynaecology, SMGS, Jammu, Jammu and Kashmir, India
  • Ankita Sharma Department of Obstetrics and Gynaecology, SMGS, Jammu, Jammu and Kashmir, India
  • Pooja Sharma Department of Obstetrics and Gynaecology, SMGS, Jammu, Jammu and Kashmir, India



EPF, Missed abortion, Mifepristone, Misoprostol


Background: Early pregnancy failure (EPF) is a common experience for women. Medical management allows for expulsion of the nonviable pregnancy in a controlled manner without any surgical risk. The aim of this study was to compare efficacy and safety of mifepristone followed by misoprostol with misoprostol alone in management of EPF.

Methods: This was a prospective comparative interventional randomised clinical study conducted at Shri Maharaja Gulab Singh hospital, Jammu, Jammu and Kashmir India from November 2019 to October 2020. A total of 200 patients with gestational age less than 13 weeks and ultrasound diagnosis of EPF were included in the study and randomly divided into two groups, group A (100 patients) received tab. mifepristone 200 mg orally 24 hrs before the use of Tab misoprostol 800 ug per vaginally. If no expulsion occurs within 4 hours, repeat doses of 400 ug misoprostol were given per vaginally at 4-hourly interval to a maximum of 2 doses in women less than or equal to 9 weeks by ultrasound and 4 doses in women more than 9 weeks by ultrasound. Group B (100 patients) received only Tab misoprostol in similar doses without prior mifepristone. The study was performed after approval from the institutional ethical committee. The data was analysed using computer software Microsoft Excel, Statistical and IBM SPSS version 21.0. The statistical difference in mean value between two groups was tested using unpaired ‘t’ test. The qualitative data was compared using Fischer’s exact test.

Results: The success rate was higher in group A 92% than group B where it was 76%. The mean induction-abortion interval and dose of misoprostol required for expulsion were 6.56±.66 hrs in group A and 10.40±4.33 hrs in group B and 1126.88±536.06 ug in group A and 1583.33±364.58 ug in group B. The patients in group A experienced significantly less side effects than those in group B, 19% versus 32% and also required fewer blood transfusions than group B, 2% versus 5%.

Conclusions: In the present study we came to the conclusion that mifepristone followed by misoprostol is more effective, safe and acceptable than misoprostol alone.


Hemminki E. Treatment of miscarriage: current practice and rationale. Obstet gynecol. 1998;91:247-53.

American college of obstetricians and gynaecologists: Early Pregnancy Loss. Practice Bulletin No. 150, Reaffirmed 2017c. 2015.

National Institute for Health and Clinical Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. NICE Clinical Guideline 154. Manchester (UK): NICE. 2012.

Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG. 2005;112(8):1102-08.

Sinha P, Suneja A, Guleria K, Aggarwal R, Vaid NB. Comparison of Mifepristone Followed by Misoprostol with Misoprostol Alone for Treatment of Early Pregnancy Failure: A Randomized Double-Blind Placebo-Controlled Trial. J Obstetr Gynecol India. 2018;68(1):39-44.

Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Medical Abortion at the Same Time (MAST) Study Trial Group. Obstet Gynecol. 2007;109:885-94.

Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378:2161-70.

Wagaarachchi PT, Ashok PW, Narvekar N, Smith NC, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod. 2001;16(9):1849-53.

El-Refaey H, Hinshaw K, Henshaw R, Smith N, Templeton A. Medical management of missed abortion and anembryonic pregnancy. Br Med J. 1992;305:1399.

Farzaneh F, Khosravi D, Hosseini MS, Defaei S, Fazel A. Comparison of the effect between two doses of vaginal misoprostol in the termination of first-trimester pregnancy: a double-blinded randomized trial. Obstet Gynecol Int J. 2018;9(1):00311.

Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception. 2006;74(6):458-62.

Chu JJ, Devall AJ, Beeson LE, Hardy P, Cheed P, Sun Y et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (Mife Miso): a randomised, double-blind, placebo-controlled trial. Lancet Elsevier Ltd. 2020;396(10253):770-8.






Original Research Articles